OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!
If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.
Requested Article:
Cholangiocarcinoma: what are the most valuable therapeutic targets – cancer-associated fibroblasts, immune cells, or beyond T cells?
Juan Wang, Emilien Loeuillard, Gregory J. Gores, et al.
Expert Opinion on Therapeutic Targets (2021) Vol. 25, Iss. 10, pp. 835-845
Open Access | Times Cited: 12
Juan Wang, Emilien Loeuillard, Gregory J. Gores, et al.
Expert Opinion on Therapeutic Targets (2021) Vol. 25, Iss. 10, pp. 835-845
Open Access | Times Cited: 12
Showing 12 citing articles:
Cholangiocarcinoma — novel biological insights and therapeutic strategies
Sumera I. Ilyas, Silvia Affò, Lipika Goyal, et al.
Nature Reviews Clinical Oncology (2023) Vol. 20, Iss. 7, pp. 470-486
Open Access | Times Cited: 93
Sumera I. Ilyas, Silvia Affò, Lipika Goyal, et al.
Nature Reviews Clinical Oncology (2023) Vol. 20, Iss. 7, pp. 470-486
Open Access | Times Cited: 93
Immunobiology of cholangiocarcinoma
Jennifer L. Tomlinson, Juan W. Valle, Sumera I. Ilyas
Journal of Hepatology (2023) Vol. 79, Iss. 3, pp. 867-875
Open Access | Times Cited: 31
Jennifer L. Tomlinson, Juan W. Valle, Sumera I. Ilyas
Journal of Hepatology (2023) Vol. 79, Iss. 3, pp. 867-875
Open Access | Times Cited: 31
Heterogeneity of Cholangiocarcinoma Immune Biology
Francesca Vita, Irene Olaizola, Francesco Amato, et al.
Cells (2023) Vol. 12, Iss. 6, pp. 846-846
Open Access | Times Cited: 20
Francesca Vita, Irene Olaizola, Francesco Amato, et al.
Cells (2023) Vol. 12, Iss. 6, pp. 846-846
Open Access | Times Cited: 20
Expression of Checkpoint Molecules in the Tumor Microenvironment of Intrahepatic Cholangiocarcinoma: Implications for Immune Checkpoint Blockade Therapy
Lara R. Heij, Jan Bednarsch, Xiuxiang Tan, et al.
Cells (2023) Vol. 12, Iss. 6, pp. 851-851
Open Access | Times Cited: 11
Lara R. Heij, Jan Bednarsch, Xiuxiang Tan, et al.
Cells (2023) Vol. 12, Iss. 6, pp. 851-851
Open Access | Times Cited: 11
Cancer-Associated Fibroblasts in Cholangiocarcinoma: Current Knowledge and Possible Implications for Therapy
Michele Montori, Chiara Scorzoni, Maria Eva Argenziano, et al.
Journal of Clinical Medicine (2022) Vol. 11, Iss. 21, pp. 6498-6498
Open Access | Times Cited: 18
Michele Montori, Chiara Scorzoni, Maria Eva Argenziano, et al.
Journal of Clinical Medicine (2022) Vol. 11, Iss. 21, pp. 6498-6498
Open Access | Times Cited: 18
Infiltrating T lymphocytes and tumor microenvironment within cholangiocarcinoma: immune heterogeneity, intercellular communication, immune checkpoints
Yunyan Dai, Chenyang Dong, Zhiming Wang, et al.
Frontiers in Immunology (2025) Vol. 15
Open Access
Yunyan Dai, Chenyang Dong, Zhiming Wang, et al.
Frontiers in Immunology (2025) Vol. 15
Open Access
Research progress of T cells in cholangiocarcinoma
Zhiming Wang, Yunyan Dai, Yunpeng Zhou, et al.
Frontiers in Immunology (2025) Vol. 16
Open Access
Zhiming Wang, Yunyan Dai, Yunpeng Zhou, et al.
Frontiers in Immunology (2025) Vol. 16
Open Access
Tumor organoid-immune co-culture models: exploring a new perspective of tumor immunity
Jing Wang, Xin Tao, Jialong Zhu, et al.
Cell Death Discovery (2025) Vol. 11, Iss. 1
Open Access
Jing Wang, Xin Tao, Jialong Zhu, et al.
Cell Death Discovery (2025) Vol. 11, Iss. 1
Open Access
The Tumor Immune Microenvironment plays a Key Role in Driving the Progression of Cholangiocarcinoma
Ye Zhang, Haijiao Yan, Jun Wu
Current Cancer Drug Targets (2024) Vol. 24, Iss. 7, pp. 681-700
Closed Access | Times Cited: 3
Ye Zhang, Haijiao Yan, Jun Wu
Current Cancer Drug Targets (2024) Vol. 24, Iss. 7, pp. 681-700
Closed Access | Times Cited: 3
Immunogenomics of cholangiocarcinoma
Virag Gehl, Colm J. O’Rourke, Jesper B. Andersen
Hepatology (2023)
Closed Access | Times Cited: 2
Virag Gehl, Colm J. O’Rourke, Jesper B. Andersen
Hepatology (2023)
Closed Access | Times Cited: 2
Identification and validation of basic fibroblast growth factor as a prognostic biomarker for the response of lung adenocarcinoma patients to bevacizumab treatment
Hongtao Jiang, Ce Li, Qiang Gong, et al.
Immunobiology (2023) Vol. 228, Iss. 6, pp. 152764-152764
Open Access | Times Cited: 1
Hongtao Jiang, Ce Li, Qiang Gong, et al.
Immunobiology (2023) Vol. 228, Iss. 6, pp. 152764-152764
Open Access | Times Cited: 1
TIGIT drives the immunosuppressive environment by downregulation of metalloproteinases MMP2 and MMP14 in perihilar cholangiocarcinoma
Lara R. Heij, Konrad Reichel, Willem de Koning, et al.
bioRxiv (Cold Spring Harbor Laboratory) (2023)
Open Access
Lara R. Heij, Konrad Reichel, Willem de Koning, et al.
bioRxiv (Cold Spring Harbor Laboratory) (2023)
Open Access
